Jefferies Group Reaffirms “Hold” Rating for Radius Health Inc. (RDUS)
Radius Health Inc. (NASDAQ:RDUS)‘s stock had its “hold” rating reiterated by Jefferies Group in a research report issued on Tuesday. They presently have a $46.00 price target on the biopharmaceutical company’s stock. Jefferies Group’s price target indicates a potential downside of 16.53% from the stock’s previous close.
Several other research firms have also issued reports on RDUS. Canaccord Genuity set a $85.00 price target on Radius Health and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research report on Monday, August 8th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $70.00 price target on shares of Radius Health in a research report on Friday, August 5th. Maxim Group lowered Radius Health from a “hold” rating to a “sell” rating and set a $24.00 price target for the company. in a research report on Thursday, August 4th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Radius Health presently has a consensus rating of “Buy” and a consensus target price of $61.73.
Radius Health (NASDAQ:RDUS) opened at 55.11 on Tuesday. Radius Health has a 52-week low of $24.75 and a 52-week high of $77.10. The company’s market capitalization is $2.37 billion. The stock has a 50 day moving average of $54.45 and a 200-day moving average of $40.78.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/jefferies-group-reaffirms-hold-rating-for-radius-health-inc-rdus.html
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same period in the previous year, the firm earned ($0.61) earnings per share. On average, equities research analysts anticipate that Radius Health will post ($3.95) earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of RDUS. Macquarie Group Ltd. acquired a new position in shares of Radius Health during the second quarter worth $747,000. Royal Bank of Canada raised its position in shares of Radius Health by 4.3% in the second quarter. Royal Bank of Canada now owns 836,118 shares of the biopharmaceutical company’s stock worth $30,729,000 after buying an additional 34,694 shares during the period. Stifel Financial Corp raised its position in shares of Radius Health by 50.7% in the second quarter. Stifel Financial Corp now owns 11,376 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 3,826 shares during the period. Fiera Capital Corp acquired a new position in shares of Radius Health during the second quarter worth $21,097,000. Finally, Farallon Capital Management LLC raised its position in shares of Radius Health by 22.4% in the second quarter. Farallon Capital Management LLC now owns 1,535,000 shares of the biopharmaceutical company’s stock worth $56,411,000 after buying an additional 281,305 shares during the period. 99.91% of the stock is owned by institutional investors and hedge funds.
Radius Health Company Profile
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.